{"id":74542,"date":"2026-11-11T19:08:16","date_gmt":"2026-11-11T23:08:16","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/pfizer-secures-1-5b-blackstone-funding-to-accelerate-obesity-drug-pipeline\/74542\/"},"modified":"2026-11-11T19:08:16","modified_gmt":"2026-11-11T23:08:16","slug":"pfizer-secures-1-5b-blackstone-funding-to-accelerate-obesity-drug-pipeline","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/pfizer-secures-1-5b-blackstone-funding-to-accelerate-obesity-drug-pipeline\/74542\/","title":{"rendered":"Pfizer Secures $1.5B Blackstone Funding to Accelerate Obesity Drug Pipeline"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Pfizer (<a href=\"\/stock\/PFE\">PFE<\/a>) will receive up to $1.5 billion<\/strong> from Blackstone (<a href=\"\/stock\/BX\">BX<\/a>) Life Sciences to fund the development of its obesity pipeline through 2028.<\/li>\n<li><strong>The funding specifically targets berobenatide<\/strong>, a potential first-in-class monthly GLP-1 receptor agonist peptide for chronic weight management.<\/li>\n<li><strong>Blackstone will receive milestone-based payments<\/strong> tied to U.S. regulatory approval and commercial sales, while Pfizer retains full ownership and control.<\/li>\n<li><strong>Pfizer plans to advance over 20 trials<\/strong> in the obesity space during 2026, including 10 Phase 3 trials for berobenatide.<\/li>\n<\/ul>\n<p>Pfizer (<a href=\"\/stock\/PFE\">PFE<\/a>) and Blackstone (<a href=\"\/stock\/BX\">BX<\/a>) Life Sciences announced a strategic co-funding agreement on Wednesday, under which Blackstone will provide up to <strong>$1.5 billion<\/strong> to support Pfizer\u2019s obesity drug development. The capital injection is slated to cover development costs through <strong>2028<\/strong>, specifically focusing on the advancement of <strong>berobenatide<\/strong>. This investigational drug is a monthly injectable GLP-1 receptor agonist that Pfizer acquired through its recent acquisition of <strong>Metsera<\/strong>.<\/p>\n<p>The deal is structured as a risk-sharing partnership where Blackstone\u2019s return is contingent on the drug&#39;s success. In exchange for the funding, Blackstone is eligible to receive <strong>milestone-based payments<\/strong> and royalties following U.S. regulatory approval and the achievement of specific commercial sales targets. <em>This arrangement allows Pfizer to offload significant R&amp;D costs while maintaining full operational control and 100% ownership of the asset.<\/em><\/p>\n<p>Pfizer is aggressively positioning itself to compete with industry leaders Eli Lilly (<a href=\"\/stock\/LLY\">LLY<\/a>) and Novo Nordisk (<a href=\"\/stock\/NVO\">NVO<\/a>) in the lucrative weight-loss market. The company intends to launch more than <strong>20 clinical trials<\/strong> related to obesity and its comorbidities in 2026. Berobenatide is currently the &quot;anchor&quot; of this cardiometabolic pipeline, with <strong>10 Phase 3 trials<\/strong> either ongoing or planned to study the drug for weight management, knee osteoarthritis, and sleep apnea.<\/p>\n<p>The partnership comes at a critical time for Pfizer as it seeks to offset declining revenue from its COVID-19 portfolio. By leveraging Blackstone&#39;s capital, Pfizer&#39;s Chief Financial Officer <strong>Cecile Guegan<\/strong> noted that the company can maintain the &quot;financial capacity and flexibility&quot; to invest in its broader pipeline across other therapeutic areas like oncology. <em>Market analysts view this as a disciplined move to accelerate a high-potential program without further straining the company&#39;s internal balance sheet.<\/em><\/p>\n<p>Blackstone Life Sciences, which currently manages approximately <strong>$18 billion<\/strong> in assets, will utilize funds from its perpetual private equity strategy (<strong>BXPE<\/strong>) for this investment. This deal marks one of the largest private funding commitments for a single drug program in recent years, highlighting the high conviction in the <strong>GLP-1 market<\/strong>, which some analysts project could exceed <strong>$100 billion<\/strong> by the end of the decade.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Pfizer (PFE) will receive up to $1.5 billion from Blackstone (BX) Life Sciences to fund the development of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[34,3783,5383,5552,5555,6801,8412,10427,24023],"class_list":["post-74542","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-pfe","tag-bx","tag-biotech","tag-blackstone","tag-pfizer","tag-glp-1","tag-pharmaceutical","tag-obesity","tag-berobenatide"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/74542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=74542"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/74542\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=74542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=74542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=74542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}